David Malcom Rodman - Jul 11, 2024 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Chief Medical Officer
Signature
/s/ Adam Levy, Attorney-in-fact
Stock symbol
MLYS
Transactions as of
Jul 11, 2024
Transactions value $
$9,566
Form type
4
Date filed
7/12/2024, 04:39 PM
Previous filing
Jun 13, 2024
Next filing
Jul 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLYS Common Stock Options Exercise $2.71K +5.02K +5.48% $0.54* 96.5K Jul 11, 2024 Direct F1
transaction MLYS Common Stock Options Exercise $6.86K +6.35K +6.58% $1.08* 103K Jul 12, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Stock Option Options Exercise $0 -5.02K -14.28% $0.00 30.1K Jul 11, 2024 Common Stock 5.02K $0.54 Direct F2, F3
transaction MLYS Stock Option Options Exercise $0 -6.35K -3.34% $0.00 184K Jul 12, 2024 Common Stock 6.35K $1.08 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This balance includes 1,778 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported.
F2 Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.
F3 The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.
F4 Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023.
F5 The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.